Crizalk 250 mg Crizalk 250 mg contains crizotinib, a targeted anticancer medicine used to treat certain types of non-small cell lung cancer (NSCLC) with specific genetic changes, such as ALK or ROS1 gene rearrangements. It works by blocking abnormal proteins that send growth signals to cancer cells, helping to slow or stop their growth and spread.

Effects & Benefits Helps slow the growth of cancer cells with specific genetic mutations. Supports the treatment of ALK-positive and ROS1-positive non-small cell lung cancer. May help reduce the size of tumors in eligible patients. Helps delay disease progression. Provides a convenient oral treatment option. Supports long-term disease management under the supervision of an oncology specialist. Possible Side Effects